Oncobiologics Stock Price, News & Analysis (NASDAQ:ONS)

$1.17 -0.02 (-1.68 %)
(As of 02/22/2018 04:26 AM ET)
Previous Close$1.17
Today's Range$1.17 - $1.19
52-Week Range$0.78 - $3.52
Volume8,700 shs
Average Volume48,598 shs
Market Capitalization$30.63 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.99

About Oncobiologics (NASDAQ:ONS)

Oncobiologics logoOncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

Receive ONS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONS
CUSIPN/A
Phone609-619-3990

Debt

Debt-to-Equity Ratio-0.01%
Current Ratio0.49%
Quick Ratio0.49%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.81 million
Price / Sales7.90
Cash FlowN/A
Price / CashN/A
Book Value($1.08) per share
Price / Book-1.08

Profitability

Trailing EPSN/A
Net Income$-38,840,000.00
Net Margins-505.67%
Return on EquityN/A
Return on Assets-141.59%

Miscellaneous

Employees48
Outstanding Shares25,740,000

Oncobiologics (NASDAQ:ONS) Frequently Asked Questions

What is Oncobiologics' stock symbol?

Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."

How were Oncobiologics' earnings last quarter?

Oncobiologics Inc (NASDAQ:ONS) posted its earnings results on Wednesday, February, 14th. The company reported ($0.28) earnings per share for the quarter. The company earned $0.77 million during the quarter. View Oncobiologics' Earnings History.

Where is Oncobiologics' stock going? Where will Oncobiologics' stock price be in 2018?

3 equities research analysts have issued twelve-month price targets for Oncobiologics' shares. Their forecasts range from $3.00 to $15.00. On average, they anticipate Oncobiologics' share price to reach $9.00 in the next twelve months. View Analyst Ratings for Oncobiologics.

Who are some of Oncobiologics' key competitors?

Who are Oncobiologics' key executives?

Oncobiologics' management team includes the folowing people:

  • Pankaj Mohan Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 53)
  • Lawrence A. Kenyon, Chief Financial Officer, Corporate Secretary (Age 52)
  • Scott A. Gangloff, Senior Vice President - Development and Manufacturing (Age 43)
  • Stephen J. McAndrew Ph.D., Senior Vice President - Business Strategy & Development (Age 63)
  • Kogan Bao Ph.D., Vice President - Analytical Sciences (Age 47)
  • Elizabeth A. Yamashita, Vice President - Regulatory Affairs (Age 56)
  • Kenneth M. Bahrt M.D., Chief Medical Officer (Age 64)
  • Claudio Albrecht, Director
  • Yezan Haddadin, Director
  • Scott A. Canute, Independent Director (Age 57)

When did Oncobiologics IPO?

(ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays acted as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

Who owns Oncobiologics stock?

Oncobiologics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (8.14%). Company insiders that own Oncobiologics stock include Elizabeth A Yamashita, Lawrence A Kenyon, Pankaj Mohan, Scott A Gangloff and Stephen J Mcandrew. View Institutional Ownership Trends for Oncobiologics.

Who sold Oncobiologics stock? Who is selling Oncobiologics stock?

Oncobiologics' stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. Company insiders that have sold Oncobiologics company stock in the last year include Elizabeth A Yamashita, Lawrence A Kenyon, Pankaj Mohan and Stephen J Mcandrew. View Insider Buying and Selling for Oncobiologics.

How do I buy Oncobiologics stock?

Shares of Oncobiologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oncobiologics' stock price today?

One share of Oncobiologics stock can currently be purchased for approximately $1.17.

How big of a company is Oncobiologics?

Oncobiologics has a market capitalization of $30.63 million and generates $3.81 million in revenue each year. Oncobiologics employs 48 workers across the globe.

How can I contact Oncobiologics?

Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]


MarketBeat Community Rating for Oncobiologics (ONS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oncobiologics (NASDAQ:ONS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.332.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$9.00
Price Target Upside: 650.00% upside339.02% upside339.02% upside339.02% upside

Oncobiologics (NASDAQ:ONS) Consensus Price Target History

Price Target History for Oncobiologics (NASDAQ:ONS)

Oncobiologics (NASDAQ:ONS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2018BarclaysDowngradeOverweight -> Equal WeightLowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingBuy$15.00LowView Rating Details
4/12/2017Jefferies GroupReiterated RatingHold$3.00HighView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Oncobiologics (NASDAQ:ONS) Earnings History and Estimates Chart

Earnings by Quarter for Oncobiologics (NASDAQ:ONS)

Oncobiologics (NASDAQ ONS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018Q1 2018($0.28)$0.77 millionViewN/AView Earnings Details
8/14/2017Q3 2017($0.37)$0.30 millionViewN/AView Earnings Details
5/15/2017Q2 2017($0.80)($0.42)$1.10 million$0.30 millionViewN/AView Earnings Details
2/14/2017Q1 2017($0.79)$0.50 million$0.30 millionViewN/AView Earnings Details
8/15/2016Q3 2016($0.38)($1.60)$0.50 millionViewN/AView Earnings Details
6/27/2016Q2 2016($0.41)($0.32)$1.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Oncobiologics (NASDAQ:ONS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Oncobiologics (NASDAQ:ONS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Oncobiologics (NASDAQ ONS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.50%
Institutional Ownership Percentage: 17.99%
Insider Trades by Quarter for Oncobiologics (NASDAQ:ONS)
Institutional Ownership by Quarter for Oncobiologics (NASDAQ:ONS)

Oncobiologics (NASDAQ ONS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/4/2018Pankaj MohanCEOSell114,677$1.17$134,172.09View SEC Filing  
12/22/2017Elizabeth A. YamashitaVPSell16,170$1.13$18,272.10View SEC Filing  
12/22/2017Lawrence A. KenyonCFOSell26,165$1.13$29,566.45View SEC Filing  
12/22/2017Stephen J McandrewSVPSell15,705$1.13$17,746.65View SEC Filing  
12/19/2017Elizabeth A. YamashitaVPSell7,660$1.15$8,809.00View SEC Filing  
12/19/2017Pankaj MohanCEOSell104,131$1.15$119,750.65View SEC Filing  
11/11/2016Scott A. GangloffSVPSell37,369$3.75$140,133.75View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Oncobiologics (NASDAQ ONS) News Headlines

Source:
DateHeadline
 Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Hold" from Analysts Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 21 at 9:24 PM
Want To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed LatelyWant To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed Lately
finance.yahoo.com - February 19 at 3:58 PM
Zacks: Oncobiologics Inc (ONS) Given Consensus Rating of "Hold" by BrokeragesZacks: Oncobiologics Inc (ONS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 18 at 7:20 PM
BRIEF-Oncobiologics Inc Files For Resale Of Up To 3.9 Million SharesBRIEF-Oncobiologics Inc Files For Resale Of Up To 3.9 Million Shares
www.reuters.com - February 16 at 9:29 AM
Oncobiologics Reports First Quarter Fiscal Year 2018 ResultsOncobiologics Reports First Quarter Fiscal Year 2018 Results
finance.yahoo.com - February 14 at 3:22 PM
What You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major InvestorsWhat You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major Investors
finance.yahoo.com - February 14 at 6:10 AM
Oncobiologics Receives Positive Nasdaq Listing DeterminationOncobiologics Receives Positive Nasdaq Listing Determination
finance.yahoo.com - February 14 at 6:10 AM
Zacks: Oncobiologics Inc (ONS) Given Consensus Recommendation of "Hold" by AnalystsZacks: Oncobiologics Inc (ONS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 10 at 3:12 PM
Oncobiologics Announces Term Extension of Series A WarrantsOncobiologics Announces Term Extension of Series A Warrants
finance.yahoo.com - February 9 at 3:27 PM
 Analysts Set $11.00 Price Target for Oncobiologics Inc (ONS) Analysts Set $11.00 Price Target for Oncobiologics Inc (ONS)
www.americanbankingnews.com - February 7 at 11:42 PM
Oncobiologics (ONS) Stock Rating Upgraded by ValuEngineOncobiologics (ONS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 4 at 6:36 PM
Zacks: Analysts Set $11.00 Target Price for Oncobiologics Inc (ONS)Zacks: Analysts Set $11.00 Target Price for Oncobiologics Inc (ONS)
www.americanbankingnews.com - February 2 at 7:08 PM
Oncobiologics (ONS) Stock Rating Lowered by BarclaysOncobiologics (ONS) Stock Rating Lowered by Barclays
www.americanbankingnews.com - January 29 at 7:00 PM
Zacks: Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Oncobiologics Inc (ONS) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 25 at 3:14 PM
Comparing Oncobiologics (ONS) & Intrexon (XON)Comparing Oncobiologics (ONS) & Intrexon (XON)
www.americanbankingnews.com - January 22 at 9:10 PM
Critical Analysis: Oncobiologics (ONS) & Organovo (ONVO)Critical Analysis: Oncobiologics (ONS) & Organovo (ONVO)
www.americanbankingnews.com - January 20 at 5:26 AM
Oncobiologics (ONS) & RXi Pharmaceuticals (RXII) Head-To-Head ContrastOncobiologics (ONS) & RXi Pharmaceuticals (RXII) Head-To-Head Contrast
www.americanbankingnews.com - January 16 at 5:08 PM
Zacks: Oncobiologics Inc (ONS) Receives Consensus Rating of "Strong Buy" from AnalystsZacks: Oncobiologics Inc (ONS) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - January 9 at 8:12 AM
Pankaj Mohan Sells 114,677 Shares of Oncobiologics Inc (ONS) StockPankaj Mohan Sells 114,677 Shares of Oncobiologics Inc (ONS) Stock
www.americanbankingnews.com - January 5 at 6:50 PM
Oncobiologics (ONS) & The Competition Head-To-Head ReviewOncobiologics (ONS) & The Competition Head-To-Head Review
www.americanbankingnews.com - January 4 at 3:28 PM
Stephen J. Mcandrew Sells 15,705 Shares of Oncobiologics Inc (ONS) StockStephen J. Mcandrew Sells 15,705 Shares of Oncobiologics Inc (ONS) Stock
www.americanbankingnews.com - December 28 at 5:56 PM
Insider Selling: Oncobiologics Inc (ONS) CFO Sells 26,165 Shares of StockInsider Selling: Oncobiologics Inc (ONS) CFO Sells 26,165 Shares of Stock
www.americanbankingnews.com - December 26 at 6:20 PM
Elizabeth A. Yamashita Sells 16,170 Shares of Oncobiologics Inc (ONS) StockElizabeth A. Yamashita Sells 16,170 Shares of Oncobiologics Inc (ONS) Stock
www.americanbankingnews.com - December 26 at 6:20 PM
 Oncobiologics Inc (ONS) Given $11.00 Consensus Price Target by Analysts Oncobiologics Inc (ONS) Given $11.00 Consensus Price Target by Analysts
www.americanbankingnews.com - December 25 at 10:06 AM
 Oncobiologics Inc (ONS) Given Consensus Rating of "Strong Buy" by Analysts Oncobiologics Inc (ONS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 22 at 12:20 AM
Insider Selling: Oncobiologics Inc (ONS) CEO Sells 104,131 Shares of StockInsider Selling: Oncobiologics Inc (ONS) CEO Sells 104,131 Shares of Stock
www.americanbankingnews.com - December 20 at 8:58 PM
Critical Review: Oncobiologics (ONS) & Its RivalsCritical Review: Oncobiologics (ONS) & Its Rivals
www.americanbankingnews.com - December 16 at 11:08 PM
Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?
finance.yahoo.com - December 14 at 5:15 PM
 Oncobiologics Inc (ONS) Given $11.00 Average Target Price by Brokerages Oncobiologics Inc (ONS) Given $11.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 6 at 9:38 PM
Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?
finance.yahoo.com - December 5 at 11:53 AM
Zacks: Oncobiologics, Inc. (ONS) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Oncobiologics, Inc. (ONS) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 21 at 9:52 AM
Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - November 20 at 1:55 AM
Zacks: Oncobiologics, Inc. (ONS) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Oncobiologics, Inc. (ONS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 16 at 3:36 PM

SEC Filings

Oncobiologics (NASDAQ:ONS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Oncobiologics (NASDAQ:ONS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Oncobiologics (NASDAQ ONS) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.